LEGN实时信号 | 通过Getagraph.com最大化利润

购买 19683 min ago

@ $52.08

发出时间: 16 Apr 2024 @ 02:17

回报率: -13.01%

上一信号: Apr 16 - 01:41

上一信号: 出售

回报率: -1.02 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	895 893
平均成交量	974 846
市值	8.24B
EPS	$0 ( 2024-03-11 )
下一个收益日期	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.41
ATR14	$0.0480 (0.11%)

音量相关性

長: 0.58 (weak)

短: 0.67 (moderate)

Signal:(66.462) Neutral

Legend Biotech Corp 相关性

10 最正相关
AQST	0.804

10 最负相关
MACQU	-0.813
CFACU	-0.811

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Legend Biotech Corp 相关性 - 货币/商品

-0.19
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.04
( neutral )

0.57
( weak )

-0.22
( neutral )

Legend Biotech Corp 财务报表

Annual	2023
营收:	$285.14M
毛利润:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
营收:	$285.14M
毛利润:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
营收:	$117.01M
毛利润:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
营收:	$89.79M
毛利润:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.